Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for COVID-19 in Hospitalized Patients
NCT04393311Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ulinastatin with Placebo (2 arms). Primary endpoint: Time to recovery up to 29 days. Planned start Feb 2022; status: withdrawn.
02
Drugs
ulinastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04393311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393311.